SSY GROUP (02005.HK): azithromycin tablets pass evaluation
On 3 November 2026, SSY GROUP (02005.HK) said the National Medical Products Administration approved its azithromycin dispersible tablets (0.25g) to pass the generic drug quality and efficacy consistency evaluation.
Key Highlights:
- The product is azithromycin dispersible tablets, 0.25g.
- Approval was granted by the National Medical Products Administration for passing the generic drug quality and efficacy consistency evaluation.
NewTimeSpace News: On 3 November 2026, SSY Group Limited (stock code: 02005) announced voluntarily that its azithromycin dispersible tablets (0.25g) have been approved by the National Medical Products Administration to pass the generic drug quality and efficacy consistency evaluation.
Azithromycin is a macrolide antibacterial mainly used for mild to moderate infections caused by susceptible strains of designated organisms.
- SSY GROUP (02005.HK): trustee buys 400,000 shares under restricted share award scheme at average HK$2.6122
- CSPC PHARMA (01093.HK): Phase II Trial in China of SYH2066 for RSV Launched
- SSY Group (02005.HK): labetalol API registration approved by China's NMPA
- SSY GROUP (02005.HK): Nimodipine oral solution wins production nod
- SSY GROUP (02005.HK): Ziprasidone Mesylate Approved for Registration as API for Use in Marketed Formulations
